drugset / Trial / NCT00004825
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Completed
10 enrolled
FDA Office of Orphan Products Development
Children's Hospital of Philadelphia · collab
Treatment
Summary
OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
Timeline
- Start
- 1998-05
- Primary completion
- —
- Completion
- 1998-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mecasermin | Protein / enzyme biologic | — | Subcutaneous |